Drug makers win Medicaid pricing carve-out disguised as outcome-based reform

What it does

This bill amends Medicaid and Medicare law to codify and expand 'value-based purchasing arrangements' (VBPs)—deals where drug manufacturers offer discounts or rebates tied to whether patients achieve specific health outcomes. The bill allows manufacturers to report multiple prices for the same drug under VBPs, excludes outcome-based rebates from price calculations used to set Medicaid rebates, and carves out VBP payments from federal anti-kickback rules. The primary beneficiaries are pharmaceutical manufacturers, who gain pricing flexibility and reduced rebate obligations; the bill's stated intent is to encourage outcome-focused drug pricing, but the mechanism shifts negotiating power away from Medicaid and toward manufacturers.

Why we flagged it

The bill's operative mechanism—excluding outcome-based rebates from Medicaid price calculations, permitting multiple best-price reporting, and carving VBPs out of anti-kickback enforcement—functions as a targeted pricing relief for drug manufacturers. The 'value-based' framing obscures that the primary effect is to reduce Medicaid's negotiating leverage and rebate recovery.

What the text implies

• By allowing manufacturers to exclude outcome-based rebates from average manufacturer price (AMP) calculations, the bill reduces the baseline price used to compute mandatory Medicaid rebates, lowering rebate amounts owed to states and the federal government—a direct transfer of savings from public programs to manufacturers.
• The anti-kickback exception (Section 5) permits manufacturers to make payments to states when patients fail to achieve outcomes, creating a financial incentive structure that may discourage states from enrolling high-risk or sicker patients in VBPs, potentially concentrating access among healthier populations.
• The requirement that VBPs be offered 'to all States' on identical terms may entrench manufacturer pricing power by preventing states from negotiating individually, while the 'multiple best price points' allowance lets manufacturers segment the market and avoid price transparency.
• The bill's GAO study (Section 6) is framed to examine 'access' and 'outcomes,' but does not mandate analysis of whether VBPs increase net drug spending or reduce Medicaid rebate recovery—a critical omission that suggests the study is designed to validate rather than scrutinize the policy.
• Inpatient drug VBPs (Section 4) create a new pathway for manufacturers to bypass hospital formulary negotiations and direct-purchase leverage by offering outcome-based deals that states may find attractive, further fragmenting Medicaid's collective bargaining position.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary citizens and state Medicaid programs face higher drug costs and reduced leverage in price negotiations. By allowing manufacturers to exclude outcome-based rebates from Medicaid rebate calculations and permitting multiple price points, the bill reduces the effective rebates states can demand, raising net Medicaid spending and potentially limiting access for lower-income beneficiaries. The anti-kickback carve-out further insulates manufacturers from enforcement scrutiny.

Who stands to gain

• pharmaceutical manufacturers (especially those with specialty/high-cost drugs)
• biologics manufacturers
• drug companies with rare-disease or gene-therapy portfolios

Named in the bill

Medicaid, Medicare, Social Security Act Section 1927, Social Security Act Section 1847A, Anti-Kickback Statute (Section 1128B), 340B drug pricing program, HHS Secretary, HHS Inspector General, GAO (Comptroller General), State Medicaid agencies, Bristol Myers Squibb (BMY), Gilead Sciences (GILD) — and 3 more

Where it stands

2 cosponsors: 1 Democrats, 1 Republicans.

• May 7, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• May 7, 2025 — Referred to Senate Committee on Finance · Congress.gov: “Read twice and referred to the Committee on Finance”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

5 lobbying clients named this bill on 5 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $13,642,990 in lobbying spend. A filing names 16 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 78% of bills with at least one filing.

Markwayne Mullin, the sponsor, reported $979,756 in PAC receipts in the 2026 cycle.

• Pharmaceutical Research and Manufacturers of America — $8,410,000 on 1 filing
• Pharmaceutical Care Management Association — $3,282,990 on 1 filing
• Astrazeneca Pharmaceuticals Lp — $1,680,000 on 1 filing
• Orchard Therapeutics North America — $190,000 on 1 filing
• Academy of Managed Care Pharmacy — $80,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.